Sustiva
Formulated to address human immunodeficiency virus infection, developed to mitigate viral replication and support immune health within established treatment regimens.
Strengths: 200 · 600mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Pharmacological class
NNRTI
- Minor side effects
dizziness; headache; nausea; rash
- Moderate side effects
insomnia; vivid dreams; elevated liver enzymes
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature away from moisture.
- Drug interactions
St. John's Wort; midazolam; ethinylestradiol
- Age restrictions
Paediatric use depends on weight and product formulation.
Contraindications
hypersensitivity to efavirenz; severe hepatic impairment; concurrent use of elbasvir/grazoprevir; concurrent use of voriconazole
Precautions and warnings
may cause dizziness and confusion; monitor for rash; monitor liver enzymes; avoid driving if dizziness occurs
Serious side effects
severe skin reactions — requires immediate medical attention; psychosis — requires immediate medical attention; convulsions — requires immediate medical attention
Patient summary
Formulated to address human immunodeficiency virus infection, developed to mitigate viral replication and support immune health within established treatment regimens.
Mechanism of action
Efavirenz is a non-nucleoside reverse transcriptase inhibitor. It binds directly to the HIV-1 reverse transcriptase enzyme, causing a conformational change that inhibits its activity and prevents the conversion of viral RNA into DNA, thus blocking viral proliferation.
Pregnancy and breastfeeding
Avoid during the first trimester of pregnancy due to risk of neural tube defects. Discuss alternatives with a specialist.
Sustiva
Formulated to address human immunodeficiency virus infection, developed to mitigate viral replication and support immune health within established treatment regimens.
Editorial Notes
- Active ingredient(s): Efavirenz
- Listed indication(s): HIV Infection
Usually available as
- 30 tablets - 200 mg222-200-mg-1480
- 30 tablets - 600 mg222-600-mg-1486